{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:19:57Z","timestamp":1792545597449,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ctrv.2026.103204","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:18:15Z","timestamp":1788016695000},"page":"103204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["MTAP loss in non\u2013small-cell lung Cancer and beyond: Therapeutic targeting of the MAT2A\u2013PRMT5 axis"],"prefix":"10.1016","volume":"150","author":[{"given":"Zhaohui Liao","family":"Arter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Sung Gabriel","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathleen","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Waliany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2026.103204_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103204_bb0010","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432516","article-title":"New treatment options for patients with oncogene-addicted non-small cell lung cancer focusing on EGFR-mutant tumors","volume":"44","author":"Saw","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103204_bb0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103204_bb0020","series-title":"NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 5.2026","author":"National Comprehensive Cancer Network (NCCN)","year":"2026"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103204_bb0025","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/cam4.4971","article-title":"Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency","volume":"12","author":"Ashok Kumar","year":"2023","journal-title":"Cancer Med"},{"issue":"6278","key":"10.1016\/j.ctrv.2026.103204_bb0030","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2026.103204_bb0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4684-5637-0_15","article-title":"Human 5\u2032-deoxy-5\u2032-methylthioadenosine phosphorylase: kinetic studies and catalytic mechanism","volume":"250","author":"Zappia","year":"1988","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103204_bb0040","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41392-025-02231-w","article-title":"Sulfide regulation and catabolism in health and disease","volume":"10","author":"Hou","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"7793","key":"10.1016\/j.ctrv.2026.103204_bb0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","author":"Consortium, I.T.P.-C.A.O.W.G","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103204_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104535","article-title":"Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data","volume":"10","author":"Ikushima","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103204_bb0325","doi-asserted-by":"crossref","first-page":"178","DOI":"10.18632\/oncotarget.28376","article-title":"Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss","volume":"14","author":"Bou Zerdan","year":"2023","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2026.103204_bb0330","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2026.103204_bb0335","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.lungcan.2018.09.019","article-title":"A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis","volume":"125","author":"Kinoshita","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2026.103204_bb0340","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103204_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2024.103970","article-title":"MTAP loss by immunohistochemistry predicts worse survival and poor response to pemetrexed chemotherapy in pleural mesothelioma [abstract 1725]","volume":"105","author":"Saliba","year":"2025","journal-title":"Lab Invest"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103204_bb0350","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/s41591-022-01930-z","article-title":"Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer","volume":"28","author":"Chatila","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103204_bb0355","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1097\/PAS.0000000000002297","article-title":"Prevalence of S-methyl-5\u2032-thioadenosine phosphorylase (MTAP) deficiency in human cancer: a tissue microarray study on 13,067 tumors from 149 different tumor types","volume":"48","author":"Gorbokon","year":"2024","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103204_bb0360","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103204_bb0365","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ccell.2018.03.010","article-title":"Comparative molecular analysis of gastrointestinal adenocarcinomas","volume":"33","author":"Liu","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103204_bb0370","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1159\/000009983","article-title":"MTAP gene deletion in endometrial cancer","volume":"45","author":"Wong","year":"1998","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.ctrv.2026.103204_bb0375","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103204_bb0380","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/PAI.0000000000001206","article-title":"Different frequency and clinical role for MTAP loss in pleural and peritoneal mesothelioma","volume":"32","author":"Davidson","year":"2024","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ctrv.2026.103204_bb0385","doi-asserted-by":"crossref","first-page":"101197","DOI":"10.1016\/j.neo.2025.101197","article-title":"Prognostic Role of High MTAP Expression is Reversed by the ERG Status in Prostate Cancer Treated by Radical Prostatectomy","volume":"67","author":"Gorbokon","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.ctrv.2026.103204_bb0390","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103204_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2020.151582","article-title":"Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression","volume":"48","author":"Nilforoushan","year":"2020","journal-title":"Ann Diagn Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103204_bb0055","first-page":"326","article-title":"Clinical features of patients with MTAP-deleted bladder cancer","volume":"13","author":"De Souza","year":"2023","journal-title":"Am J Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103204_bb0060","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1200\/JCO.2025.43.16_suppl.8530","article-title":"Clinical, genomic, and pathological features and therapeutic outcomes of non-small cell lung cancer with MTAP-loss","volume":"43","author":"Udagawa","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103204_bb0065","doi-asserted-by":"crossref","unstructured":"Sacher, A. E. A., A retrospective real-world evidence study of MTAP status and clinical outcomes in patients with advanced non-small cell lung cancer. . J Thorac Oncol 20(3): p. S60 - S61.","DOI":"10.1016\/S1556-0864(25)00277-1"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103204_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.11.010","article-title":"Clinical significance of MTAP deletions and their overlap with concurrent oncogenic driver alterations including EGFR in NSCLC","volume":"21","author":"Ross","year":"2026","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103204_bb0075","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-25-0960","article-title":"ELIOS: A Multicenter, molecular profiling study of patients with EGFR-mutant advanced non-small cell lung Cancer treated with first-line Osimertinib","volume":"16","author":"Piotrowska","year":"2026","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103204_bb0080","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.annonc.2026.03.001","article-title":"MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies","volume":"37","author":"Aldea","year":"2026","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103204_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100420","article-title":"Comparison of immunohistochemistry, next-generation sequencing and fluorescence in situ hybridization for detection of MTAP loss in pleural mesothelioma","volume":"37","author":"Febres-Aldana","year":"2024","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103204_bb0090","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtho.2025.08.014","article-title":"MTAP expression by immunohistochemistry: A novel biomarker in NSCLC","volume":"21","author":"Brune","year":"2026","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103204_bb0095","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.lungcan.2008.04.019","article-title":"Immunohistochemical diagnosis of methylthioadenosine phosphorylase (MTAP) deficiency in non-small cell lung carcinoma","volume":"63","author":"Watanabe","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2026.103204_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107963","article-title":"MTAP as an emerging biomarker in thoracic malignancies","volume":"197","author":"Brune","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2026.103204_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2022.152004","article-title":"Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma\/sarcomatoid pleural mesothelioma with desmoplastic features","volume":"60","author":"Sa-Ngiamwibool","year":"2022","journal-title":"Ann Diagn Pathol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103204_bb0110","first-page":"2108","article-title":"Homozygous deletion of and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103204_bb0115","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/bjc.2017.209","article-title":"Clinical study of genomic drivers in pancreatic ductal adenocarcinoma","volume":"117","author":"Barrett","year":"2017","journal-title":"Br J Cancer"},{"issue":"6278","key":"10.1016\/j.ctrv.2026.103204_bb0120","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/\u2212deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103204_bb0125","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103204_bb0130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O'Neil","year":"2017","journal-title":"Nat Rev Genet"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103204_bb0135","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ccell.2019.07.003","article-title":"Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation","volume":"36","author":"Fong","year":"2019","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.ctrv.2026.103204_bb0140","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1093\/nar\/gkp516","article-title":"PRMT5 is required for cell-cycle progression and p53 tumor suppressor function","volume":"37","author":"Scoumanne","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103204_bb0145","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted Cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103204_bb0150","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/s41591-019-0423-5","article-title":"Methionine is a metabolic dependency of tumor-initiating cells","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103204_bb0155","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10549-019-05146-7","article-title":"S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells","volume":"175","author":"Strekalova","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103204_bb0200","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.annonc.2025.08.3757","article-title":"Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers","volume":"36","author":"Gounder","year":"2025","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103204_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102961","article-title":"A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations","volume":"9","author":"Rodon","year":"2024","journal-title":"ESMO Open"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103204_bb0210","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-23-0092","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors","volume":"29","author":"Vieito","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103204_bb0220","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103204_bb0400","series-title":"A phase 1 dose-escalation study of protein arginine methyltransferase 5 (PRMT5) brain penetrant inhibitor PRT811 in patients with advanced solid tumors, including recurrent high-grade gliomas","author":"Falchook","year":"2021"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103204_bb0405","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2025.43.16_suppl.3011","article-title":"BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del): clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007","volume":"43","author":"Arbour","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103204_bb0410","series-title":"First-in-human phase 1 study of GTA182, a novel MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted advanced non-small cell lung cancer","author":"Lu","year":"2025"},{"key":"10.1016\/j.ctrv.2026.103204_bb0415","article-title":"Tango Therapeutics reports positive data from ongoing phase 1\/2 study with vopimetostat (TNG462) in patients with MTAP-deleted cancers","author":"Therapeutics","year":"2025","journal-title":"News Release"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103204_bb0160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccell.2020.12.010","article-title":"MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage","volume":"39","author":"Kalev","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103204_bb0165","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","article-title":"AMG 193, a clinical stage MTA-cooperative PRMT5 inhibitor, drives antitumor activity preclinically and in patients with MTAP-deleted cancers","volume":"15","author":"Belmontes","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103204_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102264","article-title":"TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers","volume":"52","author":"Briggs","year":"2025","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ctrv.2026.103204_bb0175","doi-asserted-by":"crossref","unstructured":"Yu, Z., et al., SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S-adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase-deleted tumors. MedComm (2020). 5(10): p. e705.","DOI":"10.1002\/mco2.705"},{"key":"10.1016\/j.ctrv.2026.103204_bb0180","series-title":"Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)","author":"Herzberg","year":"2024"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103204_bb0185","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41467-024-55316-5","article-title":"MAT2A inhibitor AG-270\/S095033 in patients with advanced malignancies: a phase I trial","volume":"16","author":"Gounder","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2026.103204_bb0190","doi-asserted-by":"crossref","unstructured":"Briggs, K, et al. , TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of solid tumors with MTAP loss, Cancer Res (2025) 85 (8_Supplement_1): 462.","DOI":"10.1158\/1538-7445.AM2025-462"},{"key":"10.1016\/j.ctrv.2026.103204_bb0195","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.BLADDER24-B027","article-title":"Abstract B027: the MAT2A inhibitor IDE397: a novel combination backbone for urothelial cancer subjects with MTAP deficiency","volume":"30","author":"Neilan","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103204_bb0215","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1021\/acs.jmedchem.4c01998","article-title":"MTA-cooperative PRMT5 inhibitors: mechanism switching through structure-based design","volume":"68","author":"Cottrell","year":"2025","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103204_bb0225","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.celrep.2016.03.043","article-title":"MTAP deletions in Cancer create vulnerability to targeting of the MAT2A\/PRMT5\/RIOK1 Axis","volume":"15","author":"Marjon","year":"2016","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103204_bb0230","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1093\/nar\/gkz200","article-title":"PRMT1 loss sensitizes cells to PRMT5 inhibition","volume":"47","author":"Gao","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103204_bb0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-21-0620","article-title":"SAM-competitive PRMT5 inhibitor PF-06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance","volume":"21","author":"Jensen-Pergakes","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2026.103204_bb0240","doi-asserted-by":"crossref","first-page":"8599","DOI":"10.1200\/JCO.2024.42.16_suppl.8599","article-title":"Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC","volume":"21","author":"Thummalapalli","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103204_bb0245","series-title":"668P The Impact of MTAP loss on response to immune checkpoint inhibitors in stage IV NSCLC: A prospective real-world analysis","first-page":"S1654","author":"El-Helali","year":"2024"},{"key":"10.1016\/j.ctrv.2026.103204_bb0250","article-title":"Tumor mutational burden in real-world patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness","volume":"7","author":"Quintanilha","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103204_bb0255","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103204_bb0260","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41698-022-00286-4","article-title":"Deletions on 9p21 are associated with worse outcomes after anti-PD-1\/PD-L1 monotherapy but not chemoimmunotherapy","volume":"6","author":"Ebot","year":"2022","journal-title":"npj Precis Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103204_bb0265","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1184802","article-title":"Suppressive effects of tumor cell-derived 5\u2032-deoxy-5\u2032-methylthioadenosine on human T cells","volume":"5","author":"Henrich","year":"2016","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103204_bb0270","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1038\/s41598-022-07697-0","article-title":"MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization","volume":"12","author":"Hansen","year":"2022","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103204_bb0275","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.ccell.2023.09.005","article-title":"Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance","volume":"41","author":"Gjuka","year":"2023","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103204_bb0280","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s43018-022-00443-5","article-title":"MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis","volume":"3","author":"Barriga","year":"2022","journal-title":"Nat Cancer"},{"issue":"14","key":"10.1016\/j.ctrv.2026.103204_bb0285","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-17-3008","article-title":"Prevalent homozygous deletions of type I interferon and defensin genes in human cancers associate with immunotherapy resistance","volume":"24","author":"Ye","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103204_bb0290","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-25-1507","article-title":"Combination of the MTA-cooperative PRMT5 inhibitor BMS-986504 and KRAS inhibitors is an effective treatment strategy for MTAP-deleted KRAS-mutant pancreatic Cancer","volume":"85","author":"Drizyte-Miller","year":"2025","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103204_bb0295","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1158\/0008-5472.CAN-25-1464","article-title":"CRISPR-drug combinatorial screening identifies effective combination treatments for MTAP-deleted Cancer","volume":"85","author":"Knoll","year":"2025","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103204_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22116131","article-title":"PRMT5 selective inhibitor enhances therapeutic efficacy of cisplatin in lung Cancer cells","volume":"22","author":"Bajbouj","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103204_bb0305","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/gutjnl-2024-332998","article-title":"Identification of PRMT5 as a therapeutic target in cholangiocarcinoma","volume":"74","author":"Elurbide","year":"2024","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103204_bb0310","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103204_bb0315","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006890","article-title":"PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis","volume":"11","author":"Wang","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103204_bb0320","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009600","article-title":"MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001180?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001180?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:21Z","timestamp":1792012341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":83,"alternative-id":["S0305737226001180"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103204","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MTAP loss in non\u2013small-cell lung Cancer and beyond: Therapeutic targeting of the MAT2A\u2013PRMT5 axis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103204"}}